Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43925   clinical trials with a EudraCT protocol, of which   7306   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-003893-29
    Sponsor's Protocol Code Number:BAY80-6946/17067
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2015-03-27
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2013-003893-29
    A.3Full title of the trial
    A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) - CHRONOS-3
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study investigating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma.
    A.3.2Name or abbreviated title of the trial where available
    Copanlisib and rituximab in relapsed iNHL
    A.4.1Sponsor's protocol code numberBAY80-6946/17067
    A.5.4Other Identifiers
    Name:Pi3K InhibitorNumber:BAY80-6946
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBayer AG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBayer AG
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBayer AG
    B.5.2Functional name of contact pointBayer Clinical Trials Contact
    B.5.3 Address:
    B.5.3.1Street Address-
    B.5.3.2Town/ cityBerlin
    B.5.3.3Post codeD-13342
    B.5.3.4CountryGermany
    B.5.4Telephone number+4930300139003
    B.5.6E-mailclinical-trials-contact@bayer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCopanlisib
    D.3.2Product code BAY84-1236
    D.3.4Pharmaceutical form Lyophilisate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCopanlisib
    D.3.9.2Current sponsor codeBAY 84-1236
    D.3.9.3Other descriptive nameBAY 80-6946 (as dihydrochloride BAY 84-1236)
    D.3.9.4EV Substance CodeSUB 32033
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRituximab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRITUXIMAB
    D.3.9.1CAS number 174722-31-7
    D.3.9.4EV Substance CodeSUB12570MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboLyophilisate for solution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with relapsed indolent B-cell non-Hodgkin's lymphoma
    E.1.1.1Medical condition in easily understood language
    Relapsed indolent B-cell non-Hodgkin's lymphoma
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10029600
    E.1.2Term Non-Hodgkin's lymphoma recurrent
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is:
    - To evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab, and who either had a treatment-free interval of ≥12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are to evaluate:
    • The following characteristics of disease-related symptoms: “time to deterioration” and “time to improvement”
    • Other radiological and clinical indicators of treatment efficacy
    • Safety and tolerability of copanlisib

    The other objectives of this study are to evaluate:
    - Pharmacokinetics
    - Biomarkers
    - Quality of life
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Ability to understand and willingness to sign written ICF. Signed ICF must be obtained before any study specific procedure.
    2. Histologically confirmed diagnosis of iNHL in CD20 positive patients, with histological subtype limited to: -Follicular lymphoma (FL) grade 1-2-3a, -Small lymphocytic lymphoma (SLL) with absolute monoclonal lymphocyte count <5x109/L at study entry, -Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), -Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)
    3. Patients must have relapsed (recurrence after complete response or presented progression after partial response) after the last rituximab, rituximab biosimilars-, or anti-CD20 monoclonal antibody (e.g. obinutuzumab) containing therapy (other previous treatment lines after rituximab are allowed). A previous regimen is defined as one of following: at least 2 mths of single-agent therapy (less than 2 mths of therapy is allowed for patients who responded to single-agent rituximab, rituximab biosimilars, or anti-CD20 monoclonal antibody); at least 2 consecutive cycles of polychemotherapy; acceptable provided there is no resistance. Patients with prior intolerance to PI3K inhibitors other than copanlisib are eligible.
    4. Non-WM patients must have at least one bi-dimensionally measurable lesion (not been previously irradiated) according to Lugano Classification. For patients with splenic MZL this requirement may be restricted to splenomegaly alone since that is usually the only manifestation of measurable disease.
    5. Patients affected by WM who do not have at least one bidimensionally measurable lesion in baseline radiologic assessment must have measurable disease, defined as presence of IgM paraprotein with a minimum IgM level ≥2 x upper limit of normal and positive immunofixation test
    6. Male/female patients ≥18 yrs of age
    7. ECOG performance status ≤2
    8. Life expectancy at least 3 mths
    9. Availability of fresh tissue and/or archival tumor tissue for central pathology (obtained within 5 yrs of the consent date) at Screening
    10. Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. This applies for time period between signing of ICF and 12 mths (for WOCBP) and 5 mths (for men) after last administration of study treatment. A high FSH level in postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. The investigator/a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%), e.g. IUD, IUS, bilateral tubal occlusion, vasectomized partner and sexual abstinence. Use of condoms by male patients required unless female partner permanently sterile
    11. Adequate baseline laboratory values collected no more than 7 days before starting study treatment: -Total bilirubin ≤1.5 x ULN (<3 x ULN for patients with Gilbert-Meulengracht syndrome or for patients with cholestasis due to compressive adenopathies of the hepatic hilum), -ALT and AST ≤2.5 x ULN (≤umm5 x ULN for patients with liver involvement by lymphoma), -Lipase ≤1.5 x ULN, -GFR ≥30 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula, -International normalized ratio (INR) ≤1.5 and partial thromboplastin time (PTT) ≤1.5 x ULN. PT can be used instead of INR if ≤1.5 x ULN, -Platelet count ≥75,000/mm3. For patients with confirmed lymphomatous bone marrow infiltration, platelet count ≥50,000/mm3. Platelet transfusion should not be given less than 7 days before exam
    collection, -Hb ≥8g/dL, Packed red blood cell transfusion or erythropoietin should not be given less than 7 days before exam
    collection, -ANC ≥1,000/mm3, For patients with confirmed lymphomatous bone marrow infiltration, ANC count ≥750 /mm3. Myeloid growth factors should not be given less than 7 days before exam collection
    12. LVEF ≥45%
    13. Patients must either: •have had a progression-free and treatmentfree interval of at least 12 mths after completion of the last rituximab, rituximab biosimilars or anti-CD20 monoclonal antibody-containing treatment
    OR • considered unfit to receive chemotherapy on reason of age, concomitant morbidities, and/or residual toxicity from previous treatments, unwillingness to receive chemotherapy. These patients must also have had a progression-free and treatment-free interval of at least 6 mths after completion of the last rituximab, rituximab biosimilars or anti-CD20 monoclonal antibody containing treatment. Patients in whom chemotherapy is contraindicated are defined by one of the following features: - Age ≥80 yrs, - Age <80 yrs and at least 1 of the following conditions: •at least 3 grade 3 CIRS-G comorbidities, OR •at least 1 grade 4 CIRS-G comorbidity (if compatible to participation in the study)
    E.4Principal exclusion criteria
    1. Previous assignment to treatment during this study
    2. Close affiliation with site
    3. FL grade 3b or transformed disease, or CLL
    4. Progression free interval or treatment free interval of less than 12 mths since the last rituximab, rituximab biosimilars-, or anti-CD20 monoclonal antibody (e.g. obinutuzumab) containing treatment (including maintenance with these drugs). For patients considered unwilling/unfit to receive chemotherapy: progression free interval or treatment free interval of less than 6 mths since the last rituximab, rituximab biosimilars-, or anti-CD20 monoclonal antibody containing treatment (including maintenance with these drugs), as assessed by the investigator
    5. Previous/concurrent cancer that is distinct in primary site or histology from indolent B-cell NHL (as described in Inc. criteria 2)within 5 yrs prior to treatm start except for curatively treated cervical carcinoma in situ, non-melanoma skin cancer, superficial bladder cancer (Ta, Tis & T1), and asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥1 yr prior to
    randomization
    6. Known lymphomatous involvement of central nervous system
    7. Congestive heart failure > NYHA class 2
    8. Unstable angina, new-onset angina. Myocardial infarction less than 6 mths before start of test drug
    9. Uncontrolled arterial Hypertension despite optimal medical management
    10. Patients with HbA1c >8.5% at Screening
    11. Arterial or venous thrombotic or embolic events such as cerebrovascular accident, DVT or pulmonary embolism within 3 mths before start of study treatment
    12. Non-healing wound, ulcer, or bone fracture
    13. Active, clinically serious infections >CTCAE Grade 2
    14. Known history of HIV infection
    15. Hepatitis B (HBV) or hepatitis C (HCV). All patients must be screened for HBV and HCV up to 28 days prior to study drug start. Patients positive for HBsAg or HBcAb will be eligible if negative for HBV-DNA, these patients should receive prophylactic antiviral therapy; patients positive for anti-HCV antibody will be eligible if negative for HCV-RNA
    16. seizure disorder requiring medication
    17. evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥CTCAE Grade 3 within 4 wks prior to start of study treatm
    19. Proteinuria of CTCAE Grade 3
    20. History/concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function
    21. Concurrent diagnosis of pheochromocytoma
    22. Pregnant or breast-feeding patients. Women of childbearing potential must have a serum pregnancy test performed a max of 7 days before start of treatm and negative result must be documented before start of treatm
    23. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy/procedure, excluding alopecia, peripheral neuropathy, and bone marrow parameters
    24. Known hypersensitivity to any of test drugs, test drug classes, or excipients in formulation
    25. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results
    26. Any illness or medical conditions that are unstable or could jeopardize safety of patients and compliance in study
    28. Treatment with investigational drugs other than PI3K inhibitors less than 28 days before start of treatment, unless evidence of progression since last treatm.
    29. Ongoing immunosuppressive therapy
    30. Radiotherapy or immuno-/chemotherapy less than 4 wks before start of treatment, unless evidence of progression since last treatm.
    31. Radioimmunotherapy or autologous transplant less than 3 mths before start of treatm, unless evidence of progression since last treatm
    32. Myeloid growth factors less than 7 days before start of treatm
    33. Blood or platelet transfusion less than 7 days before start of treatm
    34. Ongoing systemic corticosteroid therapy at daily dose higher than 15mg prednisone/equivalent. previous tx stopped or reduced to allowed dose at least 7 days before performing Screening CT/MRI. if chronic tx should be de-escalated to max allowed dose before Screening. topical/inhaled corticosteroids may be used.
    35. History of having received an allogeneic bone marrow or organ transplant
    36. Major surgical procedure/significant traumatic injury less than 28 days before start of treatment, open biopsy less than 7 days before start of treatm
    37. Anti-arrhythmic therapy
    38. Use of strong inhibitors of CYP3A4 is prohibited from Day -14 of Cycle 1 until Safety FU visit.
    39. Use of strong inducers of CYP3A4 is prohibited from Day -14 of Cycle 1 until Safety follow up visit.
    40. Documented evidence of resistance to prior treatment with idelalisib or other PI3K inhibitors 41. Prior Treatment with copanlisib
    42. Cytomegalovirus infection. Patients who are CMV PCR positive at baseline will not be eligible.
    E.5 End points
    E.5.1Primary end point(s)
    Progression free survival (PFS)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Time (in days) from randomization to PD or death from any cause (if no progression is documented). The actual date of tumor assessments will be used for this calculation. PFS for patients without PD or death at the time of analysis will be censored at the date of their last tumor evaluation. PFS for patients who have neither tumor assessments nor death after baseline will be censored at Day 1.
    E.5.2Secondary end point(s)
    - Objective tumor response rate (ORR)
    - Duration of response (DOR)
    - Complete response rate (CRR)
    - Time to progression (TTP)
    - Overall survival (OS)
    - Time to deterioration in DRS-P
    - Time to improvement in DRS-P
    E.5.2.1Timepoint(s) of evaluation of this end point
    - ORR - assessed in all patients up to the time of analysis of PFS.
    - DOR: time (in days) from first observed tumor response (CR, VGPR, PR, or MR) until PD or death from any cause, whichever is earlier
    - CRR: assessed in all patients up to the time of analysis of PFS.
    - TTP: time from randomization to PD or death related to PD, whichever is earlier
    - OS: time (in days) from randomization until death from any cause.
    - Time to deterioration in DRS-P of at least 3 points, as measured by the FLymSI-18 questionnaire.
    - Time to improvement in DRS-P of at least 3 points, as measured by the FLymSI-18 questionnaire, will be evaluated for patients with a baseline DRS-P score of 30 points or less.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Biomarkers and Quality of Life
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA60
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Austria
    Belarus
    Belgium
    Brazil
    Bulgaria
    Chile
    China
    Colombia
    France
    Germany
    Greece
    Hong Kong
    Hungary
    Ireland
    Italy
    Korea, Republic of
    Lithuania
    Luxembourg
    Malaysia
    Mexico
    New Zealand
    Philippines
    Poland
    Portugal
    Romania
    Russian Federation
    Singapore
    Slovakia
    South Africa
    Spain
    Taiwan
    Thailand
    Turkey
    Ukraine
    United States
    Vietnam
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    For each participating EU country, the end of the study according to the EU Clinical Trial Directive will be reached when the LVLS for all centers in the respective country has occurred.

    The end of study as a whole will be reached as soon as the end of the study according to the above definition has been reached in all participating countries (EU and non-EU).

    The end of study notification to Health Authorities will be based on the completion of the collection of survival data.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days30
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days30
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 180
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 270
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 150
    F.4.2.2In the whole clinical trial 450
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After the end of this study, further therapy is at the discretion of the investigator.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-05-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-04-14
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA